SCHEMBL2423911

SCHEMBL2423911

OC(c1c(F)ccc(F)c1Cl)C1CC1

nearest known ligand 0.40

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
PDE2A O00408 1/20 0.40
SLC6A2 P23975 4/20 0.32
SLC6A4 P31645 4/20 0.32
SLC6A3 Q01959 4/20 0.32
CYP2D6 P10635 2/20 0.32
IDO1 P14902 1/20 0.30
TDO2 P48775 1/20 0.30
HRH4 Q9H3N8 1/20 0.30
HRH3 Q9Y5N1 1/20 0.30
HTR2A P28223 1/20 0.30
HTR2C P28335 1/20 0.30
HTR2B P41595 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1350025 0.78 PDE2A (0.41) PDE2ASLC6A2SLC6A4SLC6A3IDO1
SCHEMBL3717829 0.78 PDE2A (0.43) PDE2ASLC6A2SLC6A4SLC6A3CYP2D6
SCHEMBL19865282 0.77 PDE2A (0.40) PDE2AHTR2AHTR2C
SCHEMBL31521474 0.74 PDE2A (0.45) PDE2ASLC6A2SLC6A4SLC6A3HTR2A
SCHEMBL28999224 0.72 PDE2A (0.34) PDE2A
SCHEMBL28018826 0.71 MET (0.36) PDE2AHTR2AHTR2C
SCHEMBL1582536 0.71 MET (0.36) PDE2AHTR2AHTR2C
SCHEMBL488432 0.71 MET (0.36) PDE2AHTR2AHTR2C
SCHEMBL30765076 0.71 MET (0.36) PDE2AHTR2AHTR2C
SCHEMBL1347684 0.70 PDE2A (0.61) PDE2ASLC6A2SLC6A4SLC6A3HRH4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2265616-B1 FURO-AND THIENO[3,2-C]PYRIDINES OSI PHARM INC (US) 2013-11-20 EP disclosed
US-8022206-B2 Furo[3,2-C]pyridines OSI Pharmaceuticals, LLC (US) 2011-09-20 US disclosed
US-8022206-B2 Furo[3,2-C]pyridines OSI Pharmaceuticals, LLC (US) 2011-09-20 US disclosed
US-8022206-B2 Furo[3,2-C]pyridines OSI Pharmaceuticals, LLC (US) 2011-09-20 US disclosed
EP-2265616-A1 FURO-AND THIENO[3,2-C]PYRIDINES OSI Pharmaceuticals, Inc. (US) 2010-12-29 EP disclosed
WO-2009100282-A1 FURO-AND THIENO[3,2-C] PYRIDINES OSI PHARMACEUTICALS, INC. (US) 2009-08-13 WO disclosed
US-20090197864-A1 Furo- and Thieno [3,2-c] Pyridines OSI PHARMACEUTICALS, INC. 2009-08-06 US disclosed
US-20090197864-A1 Furo- and Thieno [3,2-c] Pyridines OSI PHARMACEUTICALS, INC. 2009-08-06 US disclosed
US-20090197864-A1 Furo- and Thieno [3,2-c] Pyridines OSI PHARMACEUTICALS, INC. 2009-08-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090197864-A1 Furo- and Thieno [3,2-c] Pyridines RET, MET, ERBB2 PDE2A 2513/4885SLC6A2 4496/4885SLC6A4 4153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.